---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-142198"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T06:09:32.746644+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO

## Summary
- CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.
- Board appointed Fang Ni, Pharm.D., Chief Business Officer, as Interim CFO and principal financial officer effective Nov 19.
- Erika Jones, VP Finance and Corporate Controller, appointed principal accounting officer effective same date.
- Ni's base salary $388,100, eligible for up to 40% annual bonus; severance includes lump sum equal to base salary.
- Resignation and appointments are part of planned succession; no family relationships or conflicts reported.

## SEC filing metadata
- accession: 0001104659-21-142198
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/tm2133581d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-142198
- JSON: https://secwatch.observer/filing/0001104659-21-142198.json
- Plain text: https://secwatch.observer/filing/0001104659-21-142198.txt

## Key facts
- Executive change
  Thomas Leggett resigned as Chief Financial Officer at Black Diamond Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On November 16, 2021, Thomas Leggett resigned from his position as Chief Financial Officer (principal financial and accounting officer) of Black Diamond Therapeutics, Inc. (the “ Company ”) effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm
- Executive change
  Erika Jones was appointed as principal accounting officer at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: Effective November 19, 2021, the Board appointed Erika Jones, the Company’s Vice President, Finance and Corporate Controller, as principal accounting officer until a successor is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm
- Executive change
  Fang Ni was appointed as Interim Chief Financial Officer at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Effective November 19, 2021, the Board of Directors of the Company (the “ Board ”) appointed Fang Ni, Pharm. D., the Company’s Chief Business Officer, as Interim Chief Financial Officer and principal financial officer until a successor is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.